P-005 - A POST-HOC ANALYSIS OF POTENTIAL ETHNIC DIFFERENCES IN LORLATINIB PHARMACOKINETICS IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

J. Albanez¹, Y. Pithavala¹, J. Chen²; ¹Pfizer Inc., San Diego, CA, USA, ²Pfizer Inc., San Francisco, CA, USA.

Presenting Author(s)

Julia Albanez, BA

Student Pharmacist
Pfizer Inc.
La Jolla, California, United States